Tags » Pharma

Piramal Enterprises Ltd

Piramal Enterprises Ltd 

Pharmaceuticals

Market Cap.: ₹ 30,833.82 Cr.

Current Price: ₹ 1,786.95

Book Value: ₹ 751.05

Stock P/E: 30.98

Dividend Yield: 0.98%

Face Value: ₹ 2.00… 126 more words

Company Analysis

Sector-wise key expectations from Budget 2017

Latest News – With over a week left for Finance Minister Arun Jaitley to unveil the Budget 2017 on January 01, industry experts are being vocal about the expectations that they seek from the NDA-led government’s fourth Budget under the current term. 67 more words

Synergy Pharma Stock: SGYP’s Plecanitide Crosses Finish Line; Rodman


After market close on January 19, Synergy Pharmaceuticals Inc (NASDAQ: SGYP) reported that it had achieved FDA approval for its lead drug, plecanatide, in constipation-predominant…

CONTINUE

Pharma joins Gates Foundation, international governments in $1B outbreak prep group


Top drugmakers have joined with governments and nonprofits around the world to launch an alliance that’ll take a proactive approach to potential deadly outbreaks. Dubbed the…

CONTINUE

FDA OKs Constipation Drug From Synergy Pharma : HEALTH : Tech Times

The U.S. Food and Drug Administration has announced last Thursday its approval of Synergy Pharmaceuticals’s oral treatment for chronic idiopathic constipation (CIC). The one-a-day tablet,…
CONTINUE

Medical marijuana in Canada

I attended a very interesting Life Sciences Ontario (LSO) breakfast meeting on medical marijuana in Canada. Here are some key takeaways:

Production

  • Currently there are only 38 licensed producers (LPs) in Canada that grow the plant.
  • 635 more words
Health

Panacea Pharmaceuticals begins first-in-class vaccine trial for treatment-resistant prostate cancer

US-based pharma company Panacea Pharmaceuticals has enrolled the first patient on its phase 1 clinical trial investigating its first-in-class vaccine for persistent prostate cancer.

The four-site trial, being carried out in centres in Alabama, California, Nebraska and South Carolina, is investigating Panacea’s PAN-301-1 candidate – a vaccine that stimulates the immune system to destroy prostate cancer cells. 397 more words

Immunotherapy